Verywell Health on MSN4 天
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Pharm Exec2 天
Spravato’s Transformative Impact: Offering Hope and Rapid Relief for Patients with Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Medical News Today5 天
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Pharm Exec4 天
New Spravato Indication Offers Greater Flexibility and Personalization for Patients with ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Monthly Prescribing Reference5 天
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
WebMD5 天
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
verywellhealth5 天
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato was ...
pharmaphorum2 天
J&J’s Spravato for depression ‘should be much cheaper’
Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...